Meeting
2018 ASCO Annual Meeting
Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.
Authors
Reinhard Dummer
University Hospital Zürich Skin Cancer Center, Zürich, Switzerland
Reinhard Dummer , Axel Hauschild , Mario Santinami , Victoria Atkinson , Mario Mandalà , Vanna Chiarion-Sileni , James M. G. Larkin , Marta Nyakas , Caroline Dutriaux , Andrew Mark Haydon , Caroline Robert , Dirk Schadendorf , Paola Aimone , Bijoyesh Mookerjee , Catarina D. Campbell , James Garrett , Jan C. Brase , Richard Kefford , John M. Kirkwood , Georgina V. Long
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT01682083
Citation
J Clin Oncol 36, 2018 (suppl; abstr 9574)
DOI
10.1200/JCO.2018.36.15_suppl.9574
Abstract #
9574
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites.
First Author: Mahesh Y. Iddawela
Poster
2019 ASCO Annual Meeting
Molecular profiling of melanoma brain metastases (MBM) compared to primary cutaneous melanoma (CM).
First Author: Gino Kim In
Poster
2016 ASCO Annual Meeting
Comprehensive Genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).
First Author: Saad A. Khan
Poster
2014 ASCO Annual Meeting
Advanced or recurrent endometrial cancer (EC) and co-occurring mutations in multiple oncogenic pathways.
First Author: Alexandra Leary